Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice

被引:137
作者
Yang, ZG
Sun, HX [1 ]
Fang, WH
机构
[1] Zhejiang Univ, Coll Anim Sci, Hangzhou 310029, Peoples R China
[2] Zhejiang Univ, Coll Sci, Hangzhou 310027, Peoples R China
关键词
Astragalus membranaceus; saponins; haemolysis; OVA; adjuvants; proliferation; antibody;
D O I
10.1016/j.vaccine.2005.06.016
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this study, the haemolytic activities of Astragalus membranaceus saponins (AMS) and its adjuvant potentials on the cellular and humoral immune responses of ICR mice against OVA were evaluated. We determined the haemolytic activity of AMS using 0.5% rabbit red blood cell. AMS showed a slight haemolytic effect, with its haemolytic percents being 0.66% at the concentration of 500 mu g/ml. Furthermore, the adjuvant potentials of AMS at three dose levels on the cellular and humoral immune responses of ICR mice against ovalbumin (OVA) were investigated. ICR mice were immunized subcutaneously with OVA 100 mu g alone or with OVA 100 mu g dissolved in saline containing Alum (200 mu g), QuilA (10 and 20 mu g) or AMS (50, 100 or 200 mu g) on Day 1 and 15. Two weeks later (Day 28), concanavalin A (Con A)-, lipopolysaccharide (LPS)- and OVA-stimulated splenocyte proliferation and OVA-specific antibodies in serum were measured. AMS significantly enhanced the Con A-, LPS-, and OVA-induced splenocyte proliferation in the OVA-immunized mice especially at a dose of 100 mu g (P < 0.05 or P < 0.001). OVA-specific IgG, IgG1 and IgG2b antibody titers in serum were also significantly enhanced by AMS compared with OVA control group (P < 0.01 or P < 0.001). Moreover, no significant differences (P > 0.05) were observed between enhancing effect of AMS and QuilA on the OVA-specific IgG, IgG1 and IgG2b antibody responses to OVA in mice. In conclusion, the results suggest that AMS could be safely used as adjuvant with low or non-haemolytic effect. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:5196 / 5203
页数:8
相关论文
共 76 条
[41]   QS-21 structure/function studies: effect of acylation on adjuvant activity [J].
Liu, G ;
Anderson, C ;
Scaltreto, H ;
Barbon, J ;
Kensil, CR .
VACCINE, 2002, 20 (21-22) :2808-2815
[42]   PHASE-1 TRIAL OF IMMUNOLOGICAL ADJUVANT QS-21 WITH A GM2 GANGLIOSIDE-KEYHOLE LIMPET HEMOCYANIN CONJUGATE VACCINE IN PATIENTS WITH MALIGNANT-MELANOMA [J].
LIVINGSTON, PO ;
ADLURI, S ;
HELLING, F ;
YAO, TJ ;
KENSIL, CR ;
NEWMAN, MJ ;
MARCIANI, D .
VACCINE, 1994, 12 (14) :1275-1280
[43]   Astragaloside IV protects against ischemia brain injury in a murine model of transient focal ischemia [J].
Luo, YM ;
Qin, Z ;
Hong, Z ;
Zhang, XM ;
Ding, D ;
Fu, JH ;
Zhang, WD ;
Chen, J .
NEUROSCIENCE LETTERS, 2004, 363 (03) :218-223
[44]   Chemical analysis of Radix Astragali (Huangqi) in China: A comparison with its adulterants and seasonal variations [J].
Ma, XQ ;
Shi, Q ;
Duan, JA ;
Dong, TTX ;
Tsim, KWK .
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, 2002, 50 (17) :4861-4866
[45]   Development of semisynthetic triterpenoid saponin derivatives with immune stimulating activity [J].
Marciani, DJ ;
Press, JB ;
Reynolds, RC ;
Pathak, AK ;
Pathak, V ;
Gundy, LE ;
Farmer, JT ;
Koratich, MS ;
May, RD .
VACCINE, 2000, 18 (27) :3141-3151
[46]   Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins [J].
Marciani, DJ ;
Pathak, AK ;
Reynolds, RC ;
Seitz, L ;
May, RD .
INTERNATIONAL IMMUNOPHARMACOLOGY, 2001, 1 (04) :813-818
[47]  
McCaffery M, 1996, CLIN CANCER RES, V2, P679
[48]   Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations [J].
Newman, MJ ;
Wu, JY ;
Gardner, BH ;
Anderson, CA ;
Kensil, CR ;
Recchia, J ;
Coughlin, RT ;
Powell, MF .
VACCINE, 1997, 15 (09) :1001-1007
[49]   Separation and structural analysis of saponins in a bark extract from Quillaja saponaria Molina [J].
Nord, LI ;
Kenne, L .
CARBOHYDRATE RESEARCH, 1999, 320 (1-2) :70-81
[50]   Recent developments in adjuvants for vaccines against infectious diseases [J].
O'Hagan, DT ;
MacKichan, ML ;
Singh, M .
BIOMOLECULAR ENGINEERING, 2001, 18 (03) :69-85